CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Dysregulation and Diagnostic Potential of microRNA in Alzheimer’s Disease

Pan, Yaoqian, Liu, Ruizhu, Terpstra, Erin, Wang, Yanqing, Qiao, Fangfang, Wang, Jin, Tong, Yigang, Pan, Bo·2015·Journal of Alzheimer's Disease
DOI 10.3233/jad-150451
Open this paper in CoChat — free account

Abstract

Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and is considered to be the main cause of cognitive impairment in elderly people. The major symptom of AD is progressive dementia that eventually results in dysfunction of daily life. Due to the fact that AD has a long period of incubation before clinical symptoms emerge, the available therapeutic treatments can only improve the symptoms but not delay the progression of AD. Therefore, there is an urgent need to explore effective diagnostic approaches to catch and better treat the disease before clinical symptoms appear. Recent research revealed that abnormal expression of certain miRNA could have a crucial role in the pathological process of neurodegenerative disease including AD. Furthermore, given that AD patients show increased level of miRNAs in the blood and cerebrospinal fluid, miRNAs are considered promising non-invasive candidates for AD diagnosis and prognosis. Here, we reviewed the current research related to implications of miRNAs during the development of AD, summarized of actively used approaches to identifying potential miRNA biomarkers in body fluids, and discussed the diagnostic potential of microRNAs as biomarkers for AD.

Overview

Integrity signals

Registry

Crossref · 10.3233/jad-150451

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 118

  1. Hebert, 2003, Alzheimer disease in the US population: Prevalence estimates using the 2000 census, Arch Neurol, 60, 1119, 10.1001/archneur.60.8.1119 · DOI · Paper page
  2. Plassman, 2007, Prevalence of dementia in the United States: The Aging, Demographics, and Memory Study, Neuroepidemiology, 29, 125, 10.1159/000109998 · DOI · Paper page
  3. Lukiw, 2012, Studying micro RNA function and dysfunction in Alzheimer’s disease, Front Genet, 3, 327
  4. Choi, 2010, Recent cerebrospinal fluid biomarker studies of Alzheimer’s disease, Expert Rev Proteomics, 7, 919, 10.1586/epr.10.75 · DOI
  5. Morris, 1997, The challenge of characterizing normal brain aging in relation to Alzheimer’s disease, Neurobiol Aging, 18, 388, 10.1016/S0197-4580(97)00055-9 · DOI
  6. Squire, 1992, Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans, Psychol Rev, 99, 195, 10.1037/0033-295X.99.2.195 · DOI · Paper page
  7. Walhovd, 2010, Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease, AJNR Am J Neuroradiol, 31, 347, 10.3174/ajnr.A1809 · DOI · Paper page
  8. Ambros, 2004, The functions of animal microRNAs, Nature, 431, 350, 10.1038/nature02871 · DOI · Paper page
  9. Bartel, 2004, MicroRNAs: Genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  10. He, 2004, MicroRNAs: Small RNAs with a big role in gene regulation, Nat Rev Genet, 5, 522, 10.1038/nrg1379 · DOI · Paper page
  11. Kosik, 2006, The neuronal microRNA system, Nat Rev Neurosci, 7, 911, 10.1038/nrn2037 · DOI
  12. Sood, 2006, Cell-type-specific signatures of microRNAs on target mRNA expression, Proc Natl Acad Sci U S A, 103, 2746, 10.1073/pnas.0511045103 · DOI · Paper page
  13. Baek, 2008, The impact of microRNAs on protein output, Nature, 455, 64, 10.1038/nature07242 · DOI · Paper page
  14. Beuvink, 2007, A novel microarray approach reveals new tissue-specific signatures of known and predicted mammalian microRNAs, Nucleic Acids Res, 35, e52:1, 10.1093/nar/gkl1118 · DOI
  15. Castellano, 2013, Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues, Nucleic Acids Res, 41, 3339, 10.1093/nar/gks1474 · DOI
  16. Li, 2012, miRNA-155 upregulation and complement factor H deficits in Down’s syndrome, Neuroreport, 23, 168, 10.1097/WNR.0b013e32834f4eb4 · DOI
  17. Sethi, 2009, Micro-RNA abundance and stability in human brain: Secific alterations in Alzheimer’s disease temporal lobe neocortex, Neurosci Lett, 459, 100, 10.1016/j.neulet.2009.04.052 · DOI · Paper page
  18. Burmistrova, 2007, MicroRNA in schizophrenia: Genetic and expression analysis of miR-130b (22q11), Biochemistry (Mosc), 72, 578, 10.1134/S0006297907050161 · DOI
  19. Pogue, 2009, Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells, J Inorg Biochem, 103, 1591, 10.1016/j.jinorgbio.2009.05.012 · DOI · Paper page
  20. Wang, 2010, Export of microRNAs and microRNA-protective protein by mammalian cells, Nucleic Acids Res, 38, 7248, 10.1093/nar/gkq601 · DOI · Paper page
  21. Kim, 2007, A MicroRNA feedback circuit in midbrain dopamine neurons, Science, 317, 1220, 10.1126/science.1140481 · DOI · Paper page
  22. Saba, 2008, A miRNA signature of prion induced neurodegeneration, PLoS One, 3, e3652, 10.1371/journal.pone.0003652 · DOI · Paper page
  23. Lukiw, 2007, Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells, J Inorg Biochem, 101, 1265, 10.1016/j.jinorgbio.2007.06.004 · DOI
  24. Lukiw, 2007, Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus, Neuroreport, 18, 297, 10.1097/WNR.0b013e3280148e8b · DOI · Paper page
  25. Hebert, 2009, MicroRNA regulation of Alzheimer’s Amyloid precursor protein expression, Neurobiol Dis, 33, 422, 10.1016/j.nbd.2008.11.009 · DOI · Paper page
  26. Van den Hove, 2014, Epigenetically regulated microRNAs in Alzheimer’s disease, Neurobiol Aging, 35, 731, 10.1016/j.neurobiolaging.2013.10.082 · DOI
  27. Bennett, 2015, Epigenomics of Alzheimer’s disease, Transl Res, 165, 200, 10.1016/j.trsl.2014.05.006 · DOI
  28. Wang, 2008, The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1, J Neurosci, 28, 1213, 10.1523/JNEUROSCI.5065-07.2008 · DOI · Paper page
  29. Boissonneault, 2009, MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1, J Biol Chem, 284, 1971, 10.1074/jbc.M807530200 · DOI
  30. Long, 2011, MicroRNA-101 downregulates Alzheimer’s amyloid-beta precursor protein levels in human cell cultures and is differentially expressed, Biochem Biophys Res Commun, 404, 889, 10.1016/j.bbrc.2010.12.053 · DOI
  31. Delay, 2011, Alzheimer-specific variants in the 3’UTR of Amyloid precursor protein affect microRNA function, Mol Neurodegener, 6, 70, 10.1186/1750-1326-6-70 · DOI
  32. Bahr, 2012, Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases, Rejuvenation Res, 15, 189, 10.1089/rej.2011.1282 · DOI · Paper page
  33. Tiribuzi, 2014, miR128 up-regulation correlates with impaired amyloid beta(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease, Neurobiol Aging, 35, 345, 10.1016/j.neurobiolaging.2013.08.003 · DOI · Paper page
  34. Schonrock, 2012, MicroRNA networks surrounding APP and amyloid-β metabolism — Implications for Alzheimer’s disease, Exp Neurol, 235, 447, 10.1016/j.expneurol.2011.11.013 · DOI
  35. Smith, 2011, In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs, J Neurochem, 116, 240, 10.1111/j.1471-4159.2010.07097.x · DOI · Paper page
  36. Shioya, 2010, Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3, Neuropathol Appl Neurobiol, 36, 320, 10.1111/j.1365-2990.2010.01076.x · DOI · Paper page
  37. Zetterberg, 2010, Amyloid beta and APP as biomarkers for Alzheimer’s disease, Exp Gerontol, 45, 23, 10.1016/j.exger.2009.08.002 · DOI
  38. Stefani, 2005, AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis, J Neurol Sci, 237, 83, 10.1016/j.jns.2005.05.016 · DOI
  39. Vassar, 1999, Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE, Science, 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
  40. Magen, 2014, Oligonucleotide-based therapy for neurodegenerative diseases, Brain Res, 1584, 116, 10.1016/j.brainres.2014.04.005 · DOI
  41. Hampel, 2009, Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer’s disease, Scand J Clin Lab Invest, 69, 8, 10.1080/00365510701864610 · DOI
  42. Deng, 2014, Research status of the regulation of miRNA on BACE1, Int J Neurosci, 124, 474, 10.3109/00207454.2013.858249 · DOI
  43. Hebert, 2008, Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression, Proc Natl Acad Sci U S A, 105, 6415, 10.1073/pnas.0710263105 · DOI · Paper page
  44. Zong, 2011, miR-29c regulates BACE1 protein expression, Brain Res, 1395, 108, 10.1016/j.brainres.2011.04.035 · DOI · Paper page
  45. Wang, 2012, The potential role of microRNA-146 in Alzheimer’s disease: Biomarker or therapeutic target?, Med Hypotheses, 78, 398, 10.1016/j.mehy.2011.11.019 · DOI
  46. Geekiyanage, 2011, MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer’s disease, J Neurosci, 31, 14820, 10.1523/JNEUROSCI.3883-11.2011 · DOI · Paper page
  47. 10.1007/s12035-015-9201-7 · DOI
  48. Du, 2005, microPrimer: The biogenesis and function of microRNA, Development, 132, 4645, 10.1242/dev.02070 · DOI
  49. Goedert, 1993, Tau protein and the neurofibrillary pathology of Alzheimer’s disease, Trends Neurosci, 16, 460, 10.1016/0166-2236(93)90078-Z · DOI
  50. Carrettiero, 2009, The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule, J Neurosci, 29, 2151, 10.1523/JNEUROSCI.4660-08.2009 · DOI
  51. Hebert, 2012, MicroRNAs and the regulation of tau metabolism, Int J Alzheimers Dis, 2012, 406561
  52. Smith, 2011, MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy, Hum Mol Genet, 20, 4016, 10.1093/hmg/ddr330 · DOI · Paper page
  53. Dickson, 2013, Alternative polyadenylation and miR-34 family members regulate tau expression, J Neurochem, 127, 739, 10.1111/jnc.12437 · DOI
  54. Julien, 2009, Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease, J Neuropathol Exp Neurol, 68, 48, 10.1097/NEN.0b013e3181922348 · DOI
  55. Ramachandran, 2011, Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic beta-islets, FEBS J, 278, 1167, 10.1111/j.1742-4658.2011.08042.x · DOI
  56. Zovoilis, 2011, microRNA-34c is a novel target to treat dementias, EMBO J, 30, 4299, 10.1038/emboj.2011.327 · DOI · Paper page
  57. Zhao, 2014, MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer’s disease, Neuroscience, 275, 232, 10.1016/j.neuroscience.2014.06.013 · DOI
  58. Perry, 2009, Divergent intracellular pathways regulate interleukin-1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells, FEBS Lett, 583, 3349, 10.1016/j.febslet.2009.09.038 · DOI
  59. Lukiw, 2012, Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer’s disease (AD) brain, Mol Neurobiol, 46, 11, 10.1007/s12035-012-8234-4 · DOI · Paper page
  60. Lukiw, 2012, Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA, Neuroreport, 23, 621
  61. Zhao, 2014, Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer’s disease (AD) and in primary human neuronal-glial (HNG) cells, Mol Neurobiol, 50, 97, 10.1007/s12035-013-8595-3 · DOI
  62. Olivieri, 2013, Circulating inflamma-miRs in aging and age-related diseases, Front Genet, 4, 121, 10.3389/fgene.2013.00121 · DOI
  63. Lee, 2012, Evidence of early involvement of apoptosis inducing factor-induced neuronal death in Alzheimer brain, Anat Cell Biol, 45, 26, 10.5115/acb.2012.45.1.26 · DOI
  64. Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci U S A, 102, 13944, 10.1073/pnas.0506654102 · DOI
  65. Fang, 2012, The miR-124 regulates the expression of BACE1/beta-secretase correlated with cell death in Alzheimer’s disease, Toxicol Lett, 209, 94, 10.1016/j.toxlet.2011.11.032 · DOI
  66. Sun, 2014, miR-342-5p decreases ankyrin G levels in Alzheimer’s disease transgenic mouse models, Cell Rep, 6, 264, 10.1016/j.celrep.2013.12.028 · DOI
  67. Calin, 2007, Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas, Cancer Cell, 12, 215, 10.1016/j.ccr.2007.07.027 · DOI
  68. Marx, 2007, Alzheimer’s disease. A new take on tau, Science, 316, 1416, 10.1126/science.316.5830.1416 · DOI
  69. Craft, 2006, Insulin resistance syndrome and Alzheimer disease: Pathophysiologic mechanisms and therapeutic implications, Alzheimer Dis Assoc Disord, 20, 298, 10.1097/01.wad.0000213866.86934.7e · DOI
  70. Fehlbaum-Beurdeley, 2012, Validation of AclarusDx, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease, J Alzheimers Dis, 32, 169, 10.3233/JAD-2012-120637 · DOI
  71. Xu, 2012, Metabolomics: A novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease, Neurosci Bull, 28, 641, 10.1007/s12264-012-1272-0 · DOI
  72. Ishikawa, 2013, Plasma and serum from nonfasting men and women differ in their lipidomic profiles, Biol Pharm Bull, 36, 682, 10.1248/bpb.b12-00799 · DOI
  73. Sheinerman, 2013, Early detection of neurodegenerative diseases: Circulating brain-enriched microRNA, Cell Cycle, 12, 1, 10.4161/cc.23067 · DOI
  74. Zandberga, 2013, Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer, Genes Chromosomes Cancer, 52, 356, 10.1002/gcc.22032 · DOI
  75. Qin, 2013, An empirical evaluation of normalization methods for MicroRNA arrays in a liposarcoma study, Cancer Inform, 12, 83, 10.4137/CIN.S11384 · DOI
  76. Williams, 2013, Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations, Proc Natl Acad Sci U S A, 110, 4255, 10.1073/pnas.1214046110 · DOI
  77. Leidner, 2013, Dampening enthusiasm for circulating microRNA in breast cancer, PLoS One, 8, e57841, 10.1371/journal.pone.0057841 · DOI
  78. Boeri, 2011, MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer, Proc Natl Acad Sci U S A, 108, 3713, 10.1073/pnas.1100048108 · DOI · Paper page
  79. Cuk, 2013, Circulating microRNAs in plasma as early detection markers for breast cancer, Int J Cancer, 132, 1602, 10.1002/ijc.27799 · DOI
  80. Sheinerman, 2012, Plasma microRNA biomarkers for detection of mild cognitive impairment, Aging (Albany NY), 4, 590, 10.18632/aging.100486 · DOI · Paper page
  81. Meyer, 2010, Normalization strategies for microRNA profiling experiments: A ‘normal’ way to a hidden layer of complexity?, Biotechnol Lett, 32, 1777, 10.1007/s10529-010-0380-z · DOI
  82. Sarkar, 2009, Quality assessment and data analysis for microRNA expression arrays, Nucleic Acids Res, 37, e17, 10.1093/nar/gkn932 · DOI
  83. Kroh, 2010, Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR), Methods, 50, 298, 10.1016/j.ymeth.2010.01.032 · DOI
  84. Peltier, 2008, Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues, RNA, 14, 844, 10.1261/rna.939908 · DOI · Paper page
  85. Latham, 2010, Normalization of microRNA quantitative RT-PCR data in reduced scale experimental designs, Methods Mol Biol, 667, 19, 10.1007/978-1-60761-811-9_2 · DOI
  86. Sanders, 2012, Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma, Int J Urol, 19, 1017, 10.1111/j.1442-2042.2012.03082.x · DOI
  87. Kheirelseid, 2013, miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy, Int J Colorectal Dis, 28, 247, 10.1007/s00384-012-1549-9 · DOI
  88. Matthaei, 2012, miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts, Clin Cancer Res, 18, 4713, 10.1158/1078-0432.CCR-12-0035 · DOI
  89. Kim, 2014, Genetic markers for diagnosis and pathogenesis of Alzheimer’s disease, Genet, 545, 185
  90. Puglielli, 2003, Alzheimer’s disease: The cholesterol connection, Nat Neurosci, 6, 345, 10.1038/nn0403-345 · DOI · Paper page
  91. Koturbash, 2011, Sex-specific radiation-induced microRNAome responses in the hippocampus, cerebellum and frontal cortex in a mouse model, Mutat Res, 722, 114, 10.1016/j.mrgentox.2010.05.007 · DOI
  92. Kiko, 2014, MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease, J Alzheimers Dis, 39, 253, 10.3233/JAD-130932 · DOI · Paper page
  93. Pogue, 2014, MicroRNA (miRNA): Sequence and stability, viroid-like properties, and disease association in the CNS, Brain Res, 1584, 73, 10.1016/j.brainres.2014.03.042 · DOI
  94. Li, 2011, Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging, Aging (Albany NY), 3, 985, 10.18632/aging.100371 · DOI
  95. Ferreiro, 2007, Bcl-2 overexpression protects against amyloid-beta and prion toxicity in GT1-7 neural cells, J Alzheimers Dis, 12, 223, 10.3233/JAD-2007-12303 · DOI
  96. Bhatnagar, 2014, Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma, Front Mol Neurosci, 7, 2, 10.3389/fnmol.2014.00002 · DOI
  97. 10.1007/s12035-015-9156-8 · DOI
  98. Tan, 2015, Causes and consequences of MicroRNA dysregulation in neurodegenerative diseases, Mol Neurobiol, 51, 1249, 10.1007/s12035-014-8803-9 · DOI
  99. Vo, 2005, A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis, Proc Natl Acad Sci U S A, 102, 16426, 10.1073/pnas.0508448102 · DOI · Paper page
  100. Wayman, 2008, An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP, Proc Natl Acad Sci U S A, 105, 9093, 10.1073/pnas.0803072105 · DOI · Paper page
  101. Dhahbi, 2013, Deep sequencing identifies circulating mouse miRNAs that are functionally implicated in manifestations of aging and responsive to calorie restriction, Aging (Albany NY), 5, 130, 10.18632/aging.100540 · DOI · Paper page
  102. Alexandrov, 2012, microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF), Int J Biochem Mol Biol, 3, 365
  103. Lukiw, 2012, NF-small ka, CyrillicB-regulated micro RNAs (miRNAs) in primary human brain cells, Exp Neurol, 235, 484, 10.1016/j.expneurol.2011.11.022 · DOI · Paper page
  104. Fu, 2014, Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer’s disease, J Mol Neurosci, 54, 739, 10.1007/s12031-014-0356-x · DOI
  105. Hebert, 2010, Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration, Hum Mol Genet, 19, 3959, 10.1093/hmg/ddq311 · DOI
  106. Nelson, 2010, MiR-107 is reduced in Alzheimer’s disease brain neocortex: Validation study, J Alzheimers Dis, 21, 75, 10.3233/JAD-2010-091603 · DOI · Paper page
  107. Zhu, 2012, MicroRNA-195 downregulates Alzheimer’s disease amyloid-beta production by targeting BACE1, Brain Res Bull, 88, 596, 10.1016/j.brainresbull.2012.05.018 · DOI · Paper page
  108. Zhang, 2014, Screening of microRNAs associated with Alzheimer’s disease using oxidative stress cell model and different strains of senescence accelerated mice, J Neurol Sci, 338, 57, 10.1016/j.jns.2013.12.017 · DOI
  109. Vilardo, 2010, MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons, J Biol Chem, 285, 18344, 10.1074/jbc.M110.112664 · DOI
  110. Patel, 2008, MicroRNAs can regulate human APP levels, Mol Neurodegener, 3, 10, 10.1186/1750-1326-3-10 · DOI
  111. Muller, 2014, MicroRNAs in Alzheimer’s disease: Differential expression in hippocampus and cell-free cerebrospinal fluid, Neurobiol Aging, 35, 152, 10.1016/j.neurobiolaging.2013.07.005 · DOI · Paper page
  112. Lei, 2015, Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer’s disease, Int J Clin Exp Pathol, 8, 1565
  113. Barak, 2013, Opposing actions of environmental enrichment and Alzheimer’s disease on the expression of hippocampal microRNAs in mouse models, Transl Psychiatry, 3, e304, 10.1038/tp.2013.77 · DOI
  114. Pogue, 2010, Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation, Neurosci Lett, 476, 18, 10.1016/j.neulet.2010.03.054 · DOI
  115. Li, 2011, Increased expression of miRNA-146a in Alzheimer’s disease transgenic mouse models, Neurosci Lett, 487, 94, 10.1016/j.neulet.2010.09.079 · DOI · Paper page
  116. Holohan, 2012, Functional microRNAs in Alzheimer’s disease and cancer: Differential regulation of common mechanisms and pathways, Front Genet, 3, 323
  117. 10.1007/s12035-014-8989-x · DOI
  118. Absalon, 2013, MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons, J Neurosci, 33, 14645, 10.1523/JNEUROSCI.1327-13.2013 · DOI · Paper page

Cited by

Sorted by citations

See all 29

Metadata

Authors
Pan, Y., Liu, R., Terpstra, E., Wang, Y., Qiao, F., Wang, J., Tong, Y., & Pan, B.
Affiliations
  • Department of Veterinary Pathology, College of Animal Sciences, Henan Institute of Science and Technology, Xinxiang, China
  • China-Japan Union Hospital Jilin University, Changchun, Jilin, China
  • Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, SD, USA
  • State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Venue
Journal of Alzheimer's Disease
Publisher
SAGE Publications
Published
2015-11-03
Volume
49
Issue
1
Pages
1-12
ISSN
  • 1387-2877
  • 1875-8908
DOI
10.3233/jad-150451
Cited by
29
References
16

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review